Study of Oral Acetazolamide Plus Intravenous Furosemide to Treat Acute Decompensated Heart Failure Assessing Fluid Reduction, Urine Output, and Safety

What this Trial Is About

Researchers are evaluating the addition of oral acetazolamide to intravenous furosemide to treat congestion in patients with Acute Decompensated Heart Failure ADHF. This study is based on previous findings from the ADVOR trial and aims to see if oral acetazolamide can increase the success of decongestion, increase urine output, affect NT pro BNP levels, and assess the safety of this combination. The trial is conducted in single hospitals in Indonesia where intravenous acetazolamide is unavailable. This is a randomized, double-blind study with two treatment groups. One group receives intravenous furosemide plus oral acetazolamide at a dose of 250 mg every 12 hours for up to three days, while the other group receives intravenous furosemide plus a placebo orally at the same schedule. The study expects that the combination therapy group will experience faster fluid reduction, leading to shorter treatment duration and less total diuretic use. Participants diagnosed with ADHF who meet eligibility criteria will be randomized and monitored for at least three days to evaluate successful decongestion. Researchers will assess urinary output, NT pro BNP levels, renal function, and length of hospital stay up to 30 days. Kidney function will be monitored every 48 hours or as needed for up to 90 days, and urinary output is tracked until discharge and up to seven days after. The study includes safety monitoring and follow-up to evaluate overall treatment effects.

Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes